MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways.
Affiliation
Department of Cancer Studies, University of Birmingham, UK.Issue Date
1993-05
Metadata
Show full item recordAbstract
Epstein-Barr virus (EBV) transformed B lymphoblastoid cell lines (LCL) efficiently process exogenous antigens for MHC class II-restricted presentation via the chloroquine-sensitive endosomal pathway. Using MHC class II-restricted T cell clones specific for EBV structural proteins, however, we frequently observed significant responses to autologous LCL cells without the addition of exogenous virus. Such responses were reduced by pre-treating the LCL with acyclovir (ACV), a drug blocking productive EBV infection. This suggested T cell recognition of antigen synthesized by LCL cells spontaneously entering virus productive cycle, and led us to question by what route(s) MHC class II-restricted presentation of endogenously synthesized virion proteins was occurring. Cell sorting experiments, using the viral envelope glycoprotein gp340 as a surface marker of productively-infected cells, confirmed that stimulatory activity lay within the gp340-positive fraction. However, closer analysis revealed that most of these cells were not productively-infected but were EBV receptor-positive and had bound released virus. We infer that receptor-mediated delivery of released virus into the endosomal pathway is one route whereby an LCL can present endogenously synthesized EBV proteins on MHC class II molecules. To ask whether another, more direct, route of processing was possible, we used a recombinant vaccinia viral vector to express gp340 de novo in ACV-treated LCLs. Significantly, these cells presented the endogenously synthesized antigen to autologous gp340-specific T cell clones via a chloroquine-resistant pathway. In the same experiments, vaccinia-mediated expression of a signal peptide-deleted form of gp340 did not lead to T cell stimulation, suggesting that this second route of processing required entry of endogenously synthesized antigen into the endoplasmic reticulum.Citation
MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways. 1993, 5 (5):451-60 Int. Immunol.Journal
International ImmunologyDOI
10.1093/intimm/5.5.451PubMed ID
8391306Type
ArticleLanguage
enISSN
0953-8178ae974a485f413a2113503eed53cd6c53
10.1093/intimm/5.5.451
Scopus Count
Collections
Related articles
- Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones.
- Authors: Wallace LE, Wright J, Ulaeto DO, Morgan AJ, Rickinson AB
- Issue date: 1991 Jul
- In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340.
- Authors: Ulaeto D, Wallace L, Morgan A, Morein B, Rickinson AB
- Issue date: 1988 Nov
- Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
- Authors: Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, Belich M, Croom-Carter D, Lee S, Burrows SR
- Issue date: 1995 May
- A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells.
- Authors: Taylor GS, Long HM, Haigh TA, Larsen M, Brooks J, Rickinson AB
- Issue date: 2006 Sep 15
- Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4(+) T cells.
- Authors: Chen M, Shirai M, Liu Z, Arichi T, Takahashi H, Nishioka M
- Issue date: 1998 Oct